Introduction
In the US prostate cancer (PCa) is the most common solid malignancy and the second leading cause of cancer death in men [1] . Accurate risk estimates are essential for appropriate patient counseling, selection of therapy and clinical trial design. Traditionally, physician judgment has formed the basis for risk estimation, patient counseling and decision making. Clinicians' estimates, however, may be biased due to subjective and objective confounders that exist at all stages of the prediction process [2] [3] [4] [5] . To circumvent this limitation and to obtain the most accurate and reliable predictions, researchers have developed predictive/prognostic tools based on statistical models. Recently, predictive and prognostic nomograms have been introduced to complement the standard modeling techniques with the ability to predict various risks for individual patients. These decision aids consist of nomograms, risk groupings, artificial neural networks (ANNs), probability tables such as the most widely known and applied 'Partin staging tables', and classification and regression tree (CART) analyses. In 2001, we published a catalogue of PCa nomograms [6] . Within the last 6 years, the field of predictive modeling has exploded. In this review we catalogue the current nomograms available for PCa. We describe the patient populations to which they apply and the outcomes predicted, and record their individual characteristics. Moreover, this review may serve as an initial step toward a comprehensive reference guide for physicians to locate published nomograms that apply to the clinical decision at hand.
Currently available prediction tools
In the following discussion we provide an overview of recent PCa predictive tools organized by clinical states. In addition, we recorded predictor variables, the outcome of interest, the number of patients utilized to develop the tools, tool-specific features, predictive accuracy estimates, and whether internal or external validation has been performed. 
Staging nomograms
Several multivariable statistical models have been proposed to estimate pathologic stage at radical prostatectomy with the intent of facilitating treatment planning (Tables 3  and 4 [33-36,37 ,38-43,44 ,45-67] ). Of these, the 'Partin tables' represent a milestone in PCa management. Nonetheless, these tables have significant limitations. For example, the probability of extra-capsular extension (ECE) cannot be predicted in a side-specific fashion. To circumvent this limitation, Graefen et al. [68] attempted to enhance the specificity of ECE predictions by devising a regression tree analysis capable of predicting ECE in a side-specific manner. This model allows the identification of candidates for nonnerve sparing versus unilateral versus bilateral nerve sparing prostatectomy. External validation of this model yielded 70% accuracy [69] .
Similarly, Ohori et al. [54] developed a nomogram (n ¼ 763) to predict side-specific ECE (Table 4 Sampling density ¼ ratio of TRUS-derived total gland volume to the number of cores at biopsy. Internal and external [39] PSA, prostate-specific antigen. Based on the observations that exclusive transition zone cancers may be associated with elevated serum PSA levels despite organ confined status, Steuber et al. [47] devised a nomogram capable of predicting the probability of a transition zone PCa (77% accuracy). Chun et al. [45] developed and internally validated a nomogram for predicting the probability of biopsy Gleason sum upgrading (n ¼ 2982; 80% accuracy) and of significant Gleason sum upgrading (n ¼ 4789; 76% accuracy), defined as an increase in Gleason sum from 6 or less to 7 or higher or from 7 to 8-10. These nomograms are particularly useful when alternative treatment modalities, such as cryotherapy, high-intensity focused ultrasound, or active surveillance are considered in individuals with a Gleason sum of 6 or less PCa, as significant upgrading will affect 28% of patients.
Prediction of biochemical recurrence after radical prostatectomy Table 5 shows the pre and postoperative prediction of biochemical recurrence in men treated with radical prostatectomy [25, 75-85,86 ,87-99] . Kattan and colleagues [82,86 ,95,99] developed nomograms to predict the probability of disease recurrence after radical prostatectomy. These tools offer the possibility of relying on either preoperative or postoperative variables. The 5-year endpoint is insufficient to predict the likelihood of cure after radical prostatectomy, as many patients are at risk of disease recurrence beyond 5 years [100-102]. Therefore, Stephenson et al. [86 ] recently updated the preoperative nomogram by predicting the 10-year probability of biochemical recurrence after radical prostatectomy (77% accuracy). An added feature of the nomogram is the ability to estimate the probability of recurrence at any point in time from 1 to 10 years after radical prostatectomy, after accounting for disease-free interval.
After radical prostatectomy
Kattan et al. [95] also developed a postoperative nomogram for prediction of biochemical recurrence using data from 996 men treated with radical prostatectomy for clinically localized PCa by a single surgeon. This instrument uses preoperative PSA, prostatectomy Gleason sum, extracapsular extension, surgical margin status, SVI, and lymph-node involvement to predict the 7-year probability of biochemical recurrence (73% accuracy). External validation in an international cohort and African-American men yielded accuracies of 80% [96] and 0.83 [98] , respectively.
Despite the robust information contained within the nomogram, it has certain limitations. While the 7-year endpoint for disease recurrence is a reasonable estimate of the likelihood of cure, it is known that PCa recurrence can occur after 7 years [100-102]. In addition, in developing the nomogram, patients receiving adjuvant radiotherapy were considered as treatment failures. Thus, the predictions of the nomogram may be overly pessimistic, given that several of these patients would not have recurred without adjuvant therapy. Lastly, widespread PSA screening has resulted in a stage migration with a shift to more favorable pathologic features and prognosis [103] . To address these limitations, Stephenson et al. [99] updated the postoperative nomogram by including contemporary patients and extending predictions up to 10 years after radical surgery while accounting for disease- [110, 111] .
The same authors [113] developed a model that predicts 5-year biochemical recurrence-free survival after 125I-seeds brachytherapy without adjuvant hormonal therapy using pretreatment PSA, clinical stage, biopsy Gleason sum, and the coadministration of external beam radiotherapy (n ¼ 920). Two separate external validations resulted in accuracies of 61% (n ¼ 1827) and 64% (n ¼ 765). These accuracies are imperfect and therefore predictions should be interpreted with caution.
Prediction of metastatic progression
Without question, the prediction of metastasis is a more robust endpoint for management of PCa patients than simple prediction of recurrence assessed by a rising PSA (Table 7) 
Prediction of survival
Four nomograms have been devised for prediction of survival in PCa patients. Of these, one predicts causespecific survival in PCa patients exposed to hormonal therapy, regardless of the time of hormonal therapy initiation. The remaining three nomograms predict the probability of all-cause survival in patients with androgen insensitive PCa (AIPC).
Porter et al. [125] developed a nomogram for prediction of cause-specific survival in patients exposed to hormonal therapy after radical prostatectomy failure (n ¼ 114 
Prediction of life expectancy
Life expectancy plays a crucial role in treatment considerations, especially in patients who are candidates for definitive therapy ( 
Nomograms of the future-inclusion of novel biomarkers and imaging tools
The accuracy of current predictive tools is not yet perfect, and incorporation of novel biomarkers and imaging tools that are associated with the biologic behavior of PCa may potentially improve their predictive accuracy (Table 9 ) [132,133 ,134-136] .
Despite numerous reports of promising new biomarkers in the urological literature, only two studies have to date demonstrated a statistically significant improvement in predictive accuracy when biomarkers were added to established predictors in the nomogram setting [135, 136] . Kattan et al. [82] developed and internally validated a prognostic model that incorporates preoperative plasma levels of transforming growth factor-ß1 and interleukin-6 soluble receptor in the standard preoperative Kattan nomogram (based on preoperative PSA, biopsy Gleason grade, and clinical stage) to predict the probability of biochemical recurrence-free survival at 5 years after radical prostatectomy [135] . Addition of these biomarkers improved the predictive accuracy by a statistically and prognostically substantial margin relative to clinical variables alone (increase in accuracy from 75 to 83%). Before these promising findings can be used in routine clinical practice, they need to be validated in an independent external cohort.
Noninvasive diagnostic imaging, especially MRI and magnetic resonance spectroscopic imaging (MRSI), has improved in recent years and is gaining widespread acceptance for aiding diagnosis, tumor localization, staging, assessment of tumor aggressiveness, treatment planning, and follow-up in patients with PCa [137 ,138,139] . Wang et al. [133 ] recently established the incremental value of MRI/MRSI to the staging nomograms for predicting 292 Prostate cancer , and improved the overall accuracy of a previously published nomogram [43] for predicting the probability of insignificant PCa (from 73 to 85%).
Conclusion
Paucity of randomized trials in PCa makes diagnostic and treatment decisions complex. Decision rules, such as nomograms, provide evidence-based and at the same time individualized predictions of the outcome of interest. Such predictions have been repeatedly shown to be more accurate than those of clinicians, regardless of their level of expertise. The nomogram format has also been adopted by the urologic community and by several other disciplines, namely in breast cancer, colon cancer, gastric cancer and lung cancer. The exponential growth of nomogram numbers prompted some criticisms. For example, some asked whether a nomogram is needed, or how to choose the right nomogram for a given clinical question. We hope that we have explicitly answered this question by providing a comprehensive list of the existing nomograms and by demonstrating that each nomogram is designed for a very specific clinical scenario or patient population. The electronic versions of most nomograms described in this manuscript can be found at either http:// www.nomograms.org or at http://www.nomogram.org. On both sites, the tools are organized in a chronological fashion, according to the natural history of treated PCa, which makes the access and the selection of the specific tool easy and obviates the need for paper versions.
Clearly, further improvement in predictive accuracy of existing nomograms is desirable. Novel biomarkers, larger datasets, better data collection methods, and more sophisticated modeling procedures combined with center-specific models may accomplish this goal.
Unfortunately, there are no prospective randomized studies that clearly demonstrate that the use of nomograms improves patient care and although most nomogram predictions are sufficiently accurate, they require interpretation by an expert.
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